Navigation Links
AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
Date:6/23/2009

andidates for therapeutic vaccines against Alzheimer's, Parkinson's and atherosclerosis - in other words, against diseases that have so far seemed unsuitable for treatment by vaccination, but that represent markets worth billions. Vaccine candidates for four further undisclosed chronic diseases are currently being developed by AFFiRiS AG.

Asked about the success story of AFFiRiS AG and the current award, Andreas Höfler of Alfred Wieder AG said: "We are very proud of this award. Good investment tends to not only promote advances in technology, but also to promote individuals and aims that are as visionary as they are clear. Our MIG fund managers also pay particular attention to ensuring that the target markets of our potential investees are of a sufficient size, and that the businesses we finance have the potential to become international market leaders. We recognised this potential in AFFiRiS three years ago - the first big pharma deal and the current award confirm our initial analysis."

About AFFiRiS AG (as at June 2009)

AFFiRiS AG develops customised peptide-based vaccines based on its own patents. These are used to treat Alzheimer's disease, atherosclerosis, Parkinson's disease and other diseases that urgently require a medical solution and that have considerable market potential. Alzheimer's disease is currently the principal indication and two potential products are in the final stages of clinical phase I studies. In October 2008, the company succeeded in gaining GlaxoSmithKline Biologicals as its licensing partner for the Alzheimer's vaccine. The contract anticipates milestone-dependent payments of up to euro 430 million. AFFiRiS currently employs 50 highly qualified staff and recently added an additional 1,100 sqm to its premises at the St. Marx campus in Vienna, Austria (http://www.affiris.com).

    Contact at AFFiRiS AG:

    
'/>"/>
SOURCE AFFiRiS AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million
2. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
3. AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
4. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
5. The next generation: nanomagnets could replace semiconductors
6. Bioscrypts V-Station MIFARE Placed on Transportation Security Administrations Qualified Products List
7. First European IGRT School Takes Place for Radiotherapy Practitioners in UK
8. Abbott Named One of the Best Places to Launch a Career by BusinessWeek
9. Campbell Alliance Named Best Place to Work by Triangle Business Journal
10. Pharmaxis Announces Placement of $50 Million and Share Purchase Plan
11. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com announces ... in its catalogue: Global Chelating Agents ... About Chelating Agent A chelating agent ... bonds with metal ions, thereby forming a metal-ion ... metal-ions have on chemical processes, formulations, and the ...
(Date:8/27/2014)... YORK , Aug. 27, 2014 Guggenheim ... Guggenheim Partners, today announced the hiring of veteran equity ... senior equity analyst. Mr. Butler will focus on the ... our team a wealth of experience and a broad ... Ferrarie , Senior Managing Director and Head of Equities ...
(Date:8/27/2014)...  ARCH Venture Partners, one of the largest ... of seed and early-stage advanced technology companies, today ... more than $400 million in subscriptions. ARCH Venture ... by more than $150 million. "The ... potential of our approach to finding and funding ...
(Date:8/27/2014)... White City, OR (PRWEB) August 27, 2014 ... Supply Report, “Consolidation continues to reshape the look and ... in nutrition. Consumer demand for higher-quality ingredients will push ... the North American market have experienced strong market growth ... and ethical attributes in their food and cosmetics to ...
Breaking Biology Technology:Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3
... Distributor in Greece, to Purchase an Aggregate ... of Over $200,000 of Resurgex(R) in 2008, ... wholly owned subsidiary of Millennium,Biotechnologies Group, Inc. (OTC Bulletin Board: ... order for the international,distribution of the Resurgex(R) line in Greece. ...
... CAMBRIDGE, Mass., April 1, 2008 Abt ... Abt Bio-Pharma Solutions, Inc., a,wholly owned subsidiary of ... custom strategic, research and communication solutions for the,pharmaceutical, ... approach that blends decades of experience with wide,ranging ...
... MONTREAL, April 1 /PRNewswire-FirstCall/ - AEterna,Zentaris Inc. ... global biopharmaceutical company,focused on endocrine therapy and ... leading Canadian specialty pharmaceutical company, announced today,that, ... transactions under their,previously announced purchase and sale ...
Cached Biology Technology:Millennium Announces $200,000 Purchase Order From Greek Distributor 2Millennium Announces $200,000 Purchase Order From Greek Distributor 3Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc. 2AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights 2AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights 3
(Date:8/27/2014)... to Europe based upon a proxy for impact have ... ,big data, approach to scientific research. , The researchers ... ranked the top 100 pathogens affecting humans and the ... they believe, will help governments across the continent plan ... including as a result of climate change, and for ...
(Date:8/27/2014)... . , Charcot-Marie-Tooth ... affecting the peripheral nervous system. Researchers from the Department ... Medicine and University Medical Centre Gttingen have discovered that ... with the disease. These cells enwrap the nerve fibres ... the rapid transfer of electrical impulses. If Schwann cells ...
(Date:8/27/2014)... York, NY (June, 2014) Outstanding basic research, ... and a dedication to patient care have earned ... Columbia University Medical Center (CUMC) and NewYork-Presbyterian Hospital ... from the National Cancer Institute (NCI). The grant ... two NCI-designated Comprehensive Cancer Centers in New York ...
Breaking Biology News(10 mins):Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2Potential therapy for incurable Charcot-Marie-Tooth disease 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4
... has named its awardee for this year,s Alan ... Brown University. Dunn,s work involves genome analyses ... He investigates the origins of biological complexity ... research holds clues about how complex multicellular organisms, ...
... This release is available in French . ... without exposing the healthy surrounding tissue to the medication,s toxic ... medical reality, thanks to the work of Professor Sylvain Martel, ... Known for being the world,s first researcher to have guided ...
... most controversial aspects in the sustainable management of golf courses. ... the practices relating to reclaimed water at one of the ... on the course receive 83% more water than they need. ... be justified from any perspective", Mara del Pino Palacios Daz, ...
Cached Biology News:Casey Dunn to receive NSF Waterman Award 2Casey Dunn to receive NSF Waterman Award 3World first -- Localized delivery of an anti-cancer drug by remote-controlled microcarriers 2Golf courses that reuse water irrigate too much 2Golf courses that reuse water irrigate too much 3
Yersinia pestis...
Rabbit polyclonal to Olfactory Receptor LS189744 ( Abpromise for all tested applications)....
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Mouse monoclonal [11C9] to Zeralenone ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to BSA: Zeralenone...
Biology Products: